There is no specific treatment for dengue fever. Besides, the dengue vaccine has a long way to go. As any of the four dengue viruses can cause the disease, hence the vaccine must be tetravalent i.e., it needs to protect against all four viruses.
One of the primary problems in management of dengue is misinterpretation and resultant confusion because of the term ìhaemorrhagic feverî implying a significant haemorrhagic component to the patho-physiology and overshadowing the increased permeability, which causes depletion of the intravascular component. The doctor managing a dengue patient has to make evaluations of the haemodynamic state to assess for judicious fluid replacement at several points of time. A broad-angled evaluation involves integration of clinical and laboratory parameters, which are in turn summation of the disease process as well as the ongoing treatment. This understanding is crucial in guiding decisions about the volume, rate and type of fluid infusion. Most, if not all, deaths due to dengue are potentially avoidable. Thus, it was essential to frame the common guidelines on Clinical Management of Dengue for the physicians across the country.
These guidelines on clinical management of DF/DHF/DSS have been developed in consultation with the leading national and international experts in the field of clinical management of DHF. I am sure these will guide the clinicians for appropriate treatment of the patients with DF/DHF /DSS and would help in reducing the case fatality rate of DHF/ DSS.